Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 78

1.

OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor.

Gough MJ, Ruby CE, Redmond WL, Dhungel B, Brown A, Weinberg AD.

Cancer Res. 2008 Jul 1;68(13):5206-15. doi: 10.1158/0008-5472.CAN-07-6484.

PMID:
18593921
[PubMed - indexed for MEDLINE]
Free Article
2.

Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide.

Brode S, Cooke A.

Crit Rev Immunol. 2008;28(2):109-26. Review.

PMID:
18540827
[PubMed - indexed for MEDLINE]
3.

The anticancer immune response: indispensable for therapeutic success?

Zitvogel L, Apetoh L, Ghiringhelli F, André F, Tesniere A, Kroemer G.

J Clin Invest. 2008 Jun;118(6):1991-2001. doi: 10.1172/JCI35180. Review.

PMID:
18523649
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Regulatory T cells and immune tolerance.

Sakaguchi S, Yamaguchi T, Nomura T, Ono M.

Cell. 2008 May 30;133(5):775-87. doi: 10.1016/j.cell.2008.05.009. Review.

PMID:
18510923
[PubMed - indexed for MEDLINE]
Free Article
5.

Higher expression of Bax in regulatory T cells increases vascular inflammation.

Xiong Z, Song J, Yan Y, Huang Y, Cowan A, Wang H, Yang XF.

Front Biosci. 2008 May 1;13:7143-55.

PMID:
18508723
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction.

Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, Sgouroudis E, Piccirillo CA, Salomon BL, Bluestone JA.

Immunity. 2008 May;28(5):687-97. doi: 10.1016/j.immuni.2008.03.016. Epub 2008 May 8.

PMID:
18468463
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection.

Piconese S, Valzasina B, Colombo MP.

J Exp Med. 2008 Apr 14;205(4):825-39. doi: 10.1084/jem.20071341. Epub 2008 Mar 24. Erratum in: J Exp Med. 2008 Jun 9;205(6):1505.

PMID:
18362171
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Enhancement of OX40-induced apoptosis by TNF coactivation in OX40-expressing T cell lines in vitro leading to decreased targets for HIV type 1 production.

Takahashi Y, Tanaka R, Yamamoto N, Tanaka Y.

AIDS Res Hum Retroviruses. 2008 Mar;24(3):423-35. doi: 10.1089/aid.2007.0092.

PMID:
18327975
[PubMed - indexed for MEDLINE]
9.

Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models.

Sadun RE, Hsu WE, Zhang N, Nien YC, Bergfeld SA, Sabzevari H, Lutsiak ME, Khawli L, Hu P, Epstein AL.

J Immunother. 2008 Apr;31(3):235-45. doi: 10.1097/CJI.0b013e31816a88e0.

PMID:
18317364
[PubMed - indexed for MEDLINE]
10.

Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice.

Liu C, Lou Y, Lizée G, Qin H, Liu S, Rabinovich B, Kim GJ, Wang YH, Ye Y, Sikora AG, Overwijk WW, Liu YJ, Wang G, Hwu P.

J Clin Invest. 2008 Mar;118(3):1165-75. doi: 10.1172/JCI33583.

PMID:
18259609
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Targeting OX40 and OX40L for the treatment of autoimmunity and cancer.

Redmond WL, Weinberg AD.

Crit Rev Immunol. 2007;27(5):415-36. Review.

PMID:
18197805
[PubMed - indexed for MEDLINE]
12.

Regulatory T cells and tumour immunity - observations in mice and men.

Gallimore A, Godkin A.

Immunology. 2008 Feb;123(2):157-63. Epub 2007 Dec 7. Review.

PMID:
18067556
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist.

Redmond WL, Gough MJ, Charbonneau B, Ratliff TL, Weinberg AD.

J Immunol. 2007 Dec 1;179(11):7244-53.

PMID:
18025166
[PubMed - indexed for MEDLINE]
Free Article
14.

OX40 signaling directly triggers the antitumor effects of NKT cells.

Zhou D.

J Clin Invest. 2007 Nov;117(11):3169-72.

PMID:
17975660
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy.

Colombo MP, Piconese S.

Nat Rev Cancer. 2007 Nov;7(11):880-7. Review.

PMID:
17957190
[PubMed - indexed for MEDLINE]
16.

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, André F, Delaloge S, Tursz T, Kroemer G, Zitvogel L.

Nat Med. 2007 Sep;13(9):1050-9. Epub 2007 Aug 19.

PMID:
17704786
[PubMed - indexed for MEDLINE]
17.

A high-fat diet and regulatory T cells influence susceptibility to endotoxin-induced liver injury.

Ma X, Hua J, Mohamood AR, Hamad AR, Ravi R, Li Z.

Hepatology. 2007 Nov;46(5):1519-29.

PMID:
17661402
[PubMed - indexed for MEDLINE]
18.

Cutting edge: OX40 inhibits TGF-beta- and antigen-driven conversion of naive CD4 T cells into CD25+Foxp3+ T cells.

So T, Croft M.

J Immunol. 2007 Aug 1;179(3):1427-30.

PMID:
17641007
[PubMed - indexed for MEDLINE]
Free Article
19.

OX40 costimulation turns off Foxp3+ Tregs.

Vu MD, Xiao X, Gao W, Degauque N, Chen M, Kroemer A, Killeen N, Ishii N, Li XC.

Blood. 2007 Oct 1;110(7):2501-10. Epub 2007 Jun 15.

PMID:
17575071
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Combination antibody-based cancer immunotherapy.

Takeda K, Okumura K, Smyth MJ.

Cancer Sci. 2007 Sep;98(9):1297-302. Epub 2007 Jun 8. Review.

PMID:
17559424
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk